학술논문
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second-Line Therapy in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer
Document Type
Article
Author
Source
In Clinical Lung Cancer March 2015 16(2):92-99
Subject
Language
ISSN
1525-7304